India's biosimilar regulatory framework has changed more in the last decade than most development teams realize.
Phase III trials — once mandatory — can now be waived under the right scientific conditions. Indication extrapolation is now explicitly permitted. Animal studies are no longer routine. And analytical similarity has moved from a supporting role to the foundation of the entire development strategy.














